NCT03073070 is a Phase 1 clinical trial of biotin labeled RBCs in Diabetes, sponsored by Guohua An.

Who is sponsoring NCT03073070?

NCT03073070 is sponsored by Guohua An.

What drugs are being tested in NCT03073070?

Interventions in NCT03073070: biotin labeled RBCs.

What condition does NCT03073070 study?

NCT03073070 studies Diabetes, Red Blood Cell Survival.

Is NCT03073070 still recruiting?

NCT03073070 is currently completed. Last updated 8 February 2022.

Last reviewed 2022-02-08 · How we verify

NCT03073070

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

RBC Lifespan Measurement in Diabetic Children

Completed Phase 1 Last updated 8 February 2022

What this trial tests

Phase 1 trial testing biotin labeled RBCs in Diabetes in 6 participants. Completed in 15 September 2019.

Timeline

15 November 2017

Primary endpoint
15 September 2019

15 September 2019

Quick facts

Lead sponsor	Guohua An
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	non randomized
Design	parallel
Masking	none
Primary purpose	diagnostic
Enrollment	6
Start date	15 November 2017
Primary completion	15 September 2019
Estimated completion	15 September 2019
Sites	1 location across United States

Drugs / interventions tested

biotin labeled RBCs — full drug profile →

Conditions studied

Diabetes — all drugs for Diabetes →
Red Blood Cell Survival — all drugs for Red Blood Cell Survival →

Sponsor

Guohua An — full company profile →

Who can join

Adults 4 to 18, any sex, with Diabetes or Red Blood Cell Survival. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

HbA1c, a measure of mean blood glucose over the lifespan of a red blood cell (RBC), is a marker of increasing importance both for assessing glycemic control in children with known diabetes and for the diagnosis of diabetes in children. HbA1c has demonstrated poor reliability in diagnosis and management of pediatric diabetes and the most plausible reason for this unreliability is that the reference ranges of HbA1c were established based on 120-day RBC lifespan observed in adults, without considering the RBC lifespan difference between children and adults. The proposed studies will for the first time determine RBC lifespan in diabetic children

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Diabetes

Currently open trials in the same condition.

NCT07272837 — Impact of Semaglutide (Ozempic/Wegovy®) on Heart and Muscle Mass · recruiting
NCT07479134 — Production of Stem Cells for the Generation of Pancreatic Cells · NA · recruiting
NCT07441655 — Families Implementing Good Health Traditions for Life · NA · recruiting
NCT06724172 — CHIME: Comparing Health Interventions for Maternal Equity · NA · recruiting
NCT07417865 — ECHO Diabetes FQHC · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03073070 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Guohua An
Last refreshed: 8 February 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03073070.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing